Biogen (NASDAQ: BIIB) has recently received a number of price target changes and ratings updates:

  • 9/20/2016 – Biogen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $360.00 price target on the stock.
  • 9/18/2016 – Biogen was given a new $322.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 9/16/2016 – Biogen had its “hold” rating reaffirmed by analysts at Stifel Nicolaus.
  • 9/16/2016 – Biogen had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $386.00 price target on the stock.
  • 9/12/2016 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $346.47 price target on the stock.
  • 9/8/2016 – Biogen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $360.00 price target on the stock.
  • 9/6/2016 – Biogen was downgraded by analysts at Jefferies Group from a “buy” rating to a “hold” rating. They now have a $323.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 9/6/2016 – Biogen was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $346.47 price target on the stock.
  • 9/5/2016 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $352.34 price target on the stock.
  • 9/4/2016 – Biogen had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $319.00 price target on the stock.
  • 8/30/2016 – Biogen was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $326.73 price target on the stock.
  • 8/23/2016 – Biogen had its “buy” rating reaffirmed by analysts at Jefferies Group.
  • 8/17/2016 – Biogen had its price target lowered by analysts at Morgan Stanley from $385.00 to $368.00. They now have an “overweight” rating on the stock.
  • 8/16/2016 – Biogen had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $333.00 price target on the stock, up previously from $293.00.
  • 8/12/2016 – Biogen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $352.00 price target on the stock. According to Zacks, “Biogen’s multiple sclerosis (MS) franchise should continue driving the top-line while new products should do well. Cost cutting efforts should help the company achieve its guidance. Biogen also has some pipeline events lined up and the company continues to work on strengthening its product portfolio. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, which is its key area of expertise. However, Biogen does have some challenges in store. Although the company holds a strong position in the MS market, the emergence of additional PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks. Biogen’s interferon products are also under pressure with patients continuing to shift to oral therapies. The investigation into the company’s sales and promotion practices is also concerning.”
  • 8/10/2016 – Biogen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Biogen’s Q2 results were strong with earnings surpassing expectations by a huge margin & the company raising its outlook. Biogen holds a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera & Plegridy. Cost cutting efforts and MS franchise sales should help Biogen achieve its guidance. Biogen continues to work on strengthening its portfolio as well. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise. However, Biogen does have some challenges in store. Although Biogen holds a strong position in the MS market, the emergence of additional PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks. Interferon products are also under pressure with patients continuing to shift to oral therapies. The investigation into Biogen’s sales and promotion practices is also concerning.”
  • 8/10/2016 – Biogen had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $284.00 price target on the stock.
  • 8/9/2016 – Biogen had its “hold” rating reaffirmed by analysts at Leerink Swann. They now have a $367.00 price target on the stock.
  • 8/4/2016 – Biogen had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $319.00 price target on the stock.
  • 8/3/2016 – Biogen had its “hold” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $322.00 price target on the stock.
  • 8/3/2016 – Biogen had its “buy” rating reaffirmed by analysts at Morgan Stanley. They now have a $385.00 price target on the stock.
  • 8/3/2016 – Biogen had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos..
  • 8/3/2016 – Biogen was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $317.79 price target on the stock.
  • 8/2/2016 – Biogen had its price target raised by analysts at Raymond James Financial Inc. from $360.00 to $375.00. They now have a “strong-buy” rating on the stock.
  • 8/2/2016 – Biogen was downgraded by analysts at Standpoint Research from a “buy” rating to a “hold” rating.
  • 8/2/2016 – Biogen was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $299.76 price target on the stock.
  • 8/1/2016 – Biogen had its price target raised by analysts at BMO Capital Markets from $286.00 to $304.00. They now have a “market perform” rating on the stock.
  • 8/1/2016 – Biogen had its price target raised by analysts at Leerink Swann from $360.00 to $367.00. They now have a “market perform” rating on the stock.
  • 8/1/2016 – Biogen had its “positive” rating reaffirmed by analysts at Robert W. Baird. They now have a $284.00 price target on the stock, up previously from $268.00.
  • 7/27/2016 – Biogen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $321.00 price target on the stock. According to Zacks, “Biogen’s Q2 results were impressive with earnings beating estimates by a huge margin & the company raising its outlook. Estimates are up significantly following the release of Q2 results. Cost cutting efforts and MS franchise sales should help Biogen achieve its guidance. Biogen is working on strengthening its product portfolio as well. Moreover, the planned spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise. However, Biogen does have some challenges in store. Although the company holds a strong position in the MS market, the emergence of additional PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks. Biogen’s interferon products are also under pressure with patients continuing to shift to oral therapies. The investigation into the company’s sales and promotion practices is also concerning.”
  • 7/27/2016 – Biogen was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $289.05 price target on the stock.
  • 7/26/2016 – Biogen had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $319.00 price target on the stock.
  • 7/25/2016 – Biogen had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $268.00 price target on the stock.
  • 7/25/2016 – Biogen was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $265.77 price target on the stock.
  • 7/24/2016 – Biogen had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $319.00 price target on the stock.
  • 7/24/2016 – Biogen had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $287.00 price target on the stock.
  • 7/24/2016 – Biogen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $360.00 price target on the stock.

Shares of Biogen Inc. (NASDAQ:BIIB) traded down 0.34% during trading on Wednesday, reaching $306.00. 615,871 shares of the company’s stock were exchanged. The stock has a market cap of $67.05 billion, a PE ratio of 17.87 and a beta of 0.90. The stock’s 50 day moving average price is $310.32 and its 200-day moving average price is $274.85. Biogen Inc. has a 52-week low of $223.02 and a 52-week high of $333.65.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.69 by $0.52. The firm earned $2.89 billion during the quarter, compared to the consensus estimate of $2.79 billion. Biogen had a net margin of 33.97% and a return on equity of 40.59%. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.22 EPS. On average, equities research analysts forecast that Biogen Inc. will post $20.10 EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/biogen-biib-research-analysts-weekly-ratings-changes.html

In other Biogen news, CEO George A. Scangos sold 157 shares of the business’s stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $280.00, for a total value of $43,960.00. Following the completion of the sale, the chief executive officer now owns 54,779 shares of the company’s stock, valued at approximately $15,338,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is currently owned by company insiders.

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

5 Day Chart for NASDAQ:BIIB

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.